Modern antiplatelet therapy: When is clopidogrel the right choice?

September 10, 2018

In the current issue of Cardiovascular Innovations and Applications (Volume3, Number 2, 2018, pp. 149-162(14); DOI: https://doi.org/10.15212/CVIA.2017.0049 Punag Divanji and Kendrick Shunk from the University of California San Francisco and The San Francisco Veteran Affairs Hospital, San Francisco, CA, USA consider when clopidogrel is the right choice in modern antiplatelet therapy.

Platelet inhibition with aspirin is the cornerstone of medical therapy for coronary artery disease. In the era of percutaneous coronary intervention with drug-eluting stents, dual anti-platelet therapy with the addition of clopidogrel (Plavix©, Bristol-Myers Squibb, New York, NY) became the mainstay of therapy. However, with the advent of newer oral antiplatelet medications, including prasugrel (Effient©, Eli Lilly, Indianapolis, Indiana) and ticagrelor (Brilinta©, Astra-Zeneca, Cambridge, United Kingdom), choosing the appropriate platelet inhibitor has become more nuanced. The optimal regimen differs based on patient characteristics, clinical situation, and the condition being treated, with differing risk and safety profiles for these medications. The authors explore the appropriate use of antiplatelet therapy for stable ischemic heart disease, acute coronary syndrome, stroke, and peripheral vascular disease. They evaluate the data behind the use of antiplatelet therapy in patients on oral anticoagulation. By understanding the biochemistry of platelet aggregation, the pharmacology of platelet inhibitors, and the extensive clinical trial data that informs current guideline recommendations the authors aim to better understand the role of clopidogrel in patients with cardiovascular disease.
-end-
CVIA is available on the IngentaConnect platform and at Cardiovascular Innovations and Applications. Submissions may be made using ScholarOne Manuscripts. There are no author submission or article processing fees. CVIA is indexed in the ESCI, OCLC, Primo Central (Ex Libris), Sherpa Romeo, NISC (National Information Services Corporation), DOAJ and Index Copernicus Databases. Follow CVIA on Twitter @CVIA_Journal; or Facebook.

Cardiovascular Innovations and Applications

Related Clopidogrel Articles from Brightsurf:

Study reveals best anti-clotting strategy after heart valve intervention
The POPular TAVI trial has challenged current guideline recommendations on antiplatelet treatment after transcatheter aortic valve implantation (TAVI) in patients not taking oral anticoagulation.

Clopidogrel atop rivaroxaban and aspirin shows no added benefit for PAD
The results of VOYAGER PAD found that people with peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing lower extremity revascularization -- a procedure to treat blocked arteries in the leg -- had a significant reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone, according to a subgroup analysis from VOYAGER PAD presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).

Improving cardiovascular health of the most vulnerable
A two-year pilot project led by Rick Stouffer, MD, shows how the cardiovascular health of the most vulnerable patients can be improved with free medications.

Ticagrelor is as safe and effective as clopidogrel after heart attack
Patients given clot busters to treat a heart attack fared equally well if they were given the standard blood thinning medication clopidogrel versus the newer, more potent drug ticagrelor, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Stopping DAPT after one-month improved outcomes in stent patients
Patients who stopped taking aspirin one month after receiving a stent in the heart's arteries but continued taking the P2Y12 inhibitor clopidogrel fared significantly better after one year compared with those who followed the standard practice of continuing both medications, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Cilostazol-combo antiplatelet therapy reduced risk for recurrent stroke
The long-term combination of cilostazol with aspirin or clopidogrel resulted in fewer recurrent strokes than with aspirin or clopidogrel alone in high-risk patients.

Modern antiplatelet therapy: When is clopidogrel the right choice?
In the current issue of Cardiovascular Innovations and Applications (Volume3, Number 2, 2018, pp.

International study suggests combination therapy may prevent stroke in certain people
Results from an international clinical trial of more than 4880 participants, published in the New England Journal of Medicine, show that combining clopidogrel and aspirin following a small stroke or experiencing minor stroke symptoms decreases risk of a new stroke, heart attack or other ischemic event within 90 days.

Stroke prevention drug combo shows promise, study says
If you've had a minor stroke or a transient ischemic stroke (TIA), taking the clot-preventing drug clopidogrel along with aspirin may lower your risk of having a major stroke within the next 90 days, according to new research published in The New England Journal of Medicine.

Ticagrelor has comparable safety to clopidogrel after heart attack
Among people younger than 75 years who were given clot busters to treat a heart attack, taking the more potent blood thinner ticagrelor did not increase the risk of major bleeding (the primary endpoint) compared with the standard blood thinner clopidogrel, in a trial being presented at the American College of Cardiology's 67th Annual Scientific Session.

Read More: Clopidogrel News and Clopidogrel Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.